Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia

Area of Science:

• Cardiology
• Biochemistry
• Medical Technology

Background:

• High LDL cholesterol is a primary driver of premature coronary heart disease (CHD).
• Homozygous familial hypercholesterolemia (FH) in children exemplifies severe, early-onset atherosclerosis due to extreme LDL levels.
• LDL-apheresis is an established treatment for lipid-lowering drug-resistant hypercholesterolemia in FH patients.

Purpose of the Study:

• To review the established efficacy and safety of LDL-apheresis in refractory hypercholesterolemia.
• To explore potential novel clinical applications of LDL-apheresis beyond FH treatment.
• To identify the need for further research into the mechanisms and broader clinical utility of LDL-apheresis.

Main Methods:

• Review of clinical efficacy and safety data for LDL-apheresis in FH patients.
• Analysis of case reports and retrospective studies on potential new indications.
• Discussion of the technical aspects of LDL-apheresis, including whole blood adsorption via polyacrylate columns.

Main Results:

• LDL-apheresis is clinically effective and safe for severe, refractory hypercholesterolemia in FH.
• Stabilization or regression of arterial lesions has been observed.
• Potential benefits in other conditions are suggested by preliminary data, but require further investigation.

Conclusions:

• LDL-apheresis is a valuable therapeutic option for managing severe hypercholesterolemia in FH.
• Emerging evidence suggests broader applications, necessitating further research.
• Prospective randomized controlled trials are crucial to validate new clinical indications and elucidate underlying mechanisms.